Blue Toe Syndrome: Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 07.05.2026 · 1 (1)
DOI: 10.62487/saimsara2d9e6cb0 ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 07.05.2026. Die Arbeit nennt 77 Literaturangaben.
Abstract (Originalsprache)
This scoping review aims to synthesize the structured evidence on BTS, with emphasis on recurrent mechanisms, diagnostic strategies, etiologic breadth, treatment approaches, and clinically relevant outcomes reported across original human studies. The review focuses on identifying the dominant paper-level signal aligned to the query “blue toe syndrome” while preserving the heterogeneity of etiologies and study designs represented in the extracted literature. The review utilises 88 original studies with 3767 total participants (topic deduplicated ΣN). Across the mapped evidence, BTS emerged most consistently as a clinical signal of distal microembolization from aortoiliac, aneurysmal, or procedure-disrupted arterial sources, with duplex Doppler ultrasound supported as an effective first-line localization tool in a 165-patient prospective cohort and post-catheterization cholesterol embolization syndrome occurring in 1.4% of cases with elevated CRP independently predicting risk (OR 4.6). Procedural risk was further highlighted by severe aortic wall thrombus on preprocedural CT being strongly associated with thromboembolic events after transfemoral TAVR (OR 8.48, 95% CI 3.36–21.40), while historical cohorts showed 85% abnormal toe/ankle indices and 20% mortality, underscoring the prognostic weight of the finding. Beyond the dominant atheroembolic axis, the synthesis indicates a broad differential including antiphospholipid syndrome, myeloproliferative and thrombocytotic states, vasculitis, malignancy-associated thrombosis, drug- and cancer-therapy-related ischemia, and mechanical or dermatologic mimics, supporting mechanism-directed rather than uniform management. Therapeutic signals were heterogeneous, ranging from a single randomized trial of liposomal alprostadil (87.5% vs 25.0% response, p=0.002) to endovascular or surgical source exclusion, anticoagulation in selected thrombotic etiologies, and supportive care including statins or LDL apheresis for cholesterol embolization. Clinically, the mapped evidence supports treating BTS as a trigger for structured embolic-source evaluation combined with screening for systemic, hematologic, autoimmune, and iatrogenic contributors rather than as an isolated digital disorder. Future work should prioritize prospective, mechanism-stratified registries and diagnostic-pathway validation studies to clarify optimal workup sequencing and treatment selection across the heterogeneous etiologies identified in this scoping map.
Zitieren
APA
(2026). Blue Toe Syndrome: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsara2d9e6cb0
Vancouver
Blue Toe Syndrome: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsara2d9e6cb0
BibTeX
@article{euvimed2026,
title = {Blue Toe Syndrome: Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {1},
doi = {10.62487/saimsara2d9e6cb0}
}
EUVIMED